Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.
Tino SeverinsenJens Jakob ThuneHelga Lillian GudmundsdottirChristoffer Rasmus VissingKasper IversenCarolyn Yung HoHenning BundgaardAnna Axelsson RajaPublished in: American heart journal (2023)
Despite applying the potentially more sensitive composite z-score endpoint as in the VANISH trial, no statistically significant benefits from the use of losartan compared to placebo could be detected at 12-month follow-up in patients with overt HCM participating in the INHERIT trial.